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Condensation: Ovarian carcinoma patients demonstrating isolated lymph node relapse display 30 
favorable outcome and greater tumour-infiltrating T-cell burden at diagnosis compared to extra-31 
nodal relapse cases   32 
Short Title: Clinical and molecular characterisation of ILNR ovarian carcinoma 33 
AJOG at a glance: A. A number of investigators have reported a relatively indolent disease course in 34 
ovarian carcinoma patients experiencing isolated lymph node relapse (ILNR). However, none have 35 
systematically compared these to extra-nodal relapse or performed molecular characterisation of 36 
cases that go on to experience this distinct pattern of recurrence.   37 
B. ILNR patients demonstrated significantly prolonged overall and post-relapse survival compared to 38 
extra-nodal relapse cases. ILNR cases demonstrated greater tumor-infiltrating lymphocyte burden at 39 
diagnosis, but did not demonstrate significant enrichment or depletion of BRCA1/2 mutation or gain 40 
of CCNE1, both known to be prognostic in OC.  41 
C. This is the first report demonstrating significantly improved clinical outcome in ILNR ovarian 42 
carcinoma when compared directly to extra-nodal relapse, and represents the first study to perform 43 
molecular characterisation of cases that go on to experience ILNR.   44 
Key words: cancer recurrence, isolated lymph node relapse, ovarian cancer, survival, tumor-45 
infiltrating lymphocytes 46 
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Background: Disease relapse is the primary cause death from ovarian carcinoma (OC). Isolated 51 
lymph node relapse (ILNR) is a rare pattern of OC recurrence, with a reported median post-relapse 52 
survival (PRS) of 2.5-4 years. To date, investigations have not compared ILNR OC directly to a 53 
matched extra-nodal relapse (ENR) cohort or performed molecular characterization of cases that 54 
subsequently experience ILNR.  55 
Objective(s): Here we seek to compare the clinical outcome, tumour-infiltrating lymphocyte burden 56 
and frequency of known prognostic genomic events in ILNR OC versus ENR OC. 57 
Study design: 49 ILNR OC patients were identified and matched to 49 ENR cases using the Edinburgh 58 
Ovarian Cancer Database, from which the clinical data for identified patients were retrieved. 59 
Matching criteria were disease stage, histological subtype and grade, extent of residual disease 60 
following surgical debulking and age at diagnosis. Clinicopathological factors and survival data were 61 
compared between the ILNR and ENR cohorts. Genomic characterization of tumor material from 62 
diagnosis was performed using panel-based high throughput sequencing and tumor-infiltrating T-cell 63 
burden was assessed using immunohistochemistry for CD3+ and CD8+ cells. 64 
Results: ILNR cases demonstrated significantly prolonged PRS and overall survival (OS) versus ENR 65 
upon multivariable analysis (HR
multi
=0.52[0.33-0.84] and 0.51[0.31-0.84]). Diagnostic specimens from 66 
high grade serous (HGS) OCs that subsequently displayed ILNR harboured significantly greater CD3+ 67 
and CD8+ cell infiltration compared to ENR cases (P=0.001 and P=0.009, Bonferroni-adjusted 68 
P=0.003 and 0.019). ILNR HGS OC cases did not show marked enrichment or depletion of cases with 69 
BRCA1/2 mutation or CCNE1 copy number gain  when compared to their ENR counterparts (24.4% vs 70 
19.4% and 18.2% vs 22.6%, P=0.865 and P=0.900).  71 
Conclusion(s): ILNR OC represents a distinct clinical entity with favorable outcome compared to ENR. 72 















cohort compared with ENR cases, suggesting that these known prognostic genomically-defined 74 
subtypes of disease do not display markedly altered propensity for ILNR. Diagnostic tumor material 75 
from ILNR patients demonstrated greater CD3+ and CD8+ cell infiltration, indicating stronger tumor 76 
engagement by T-cell populations, which may contribute to the more indolent disease course of 77 
ILNR.  78 
 79 
 80 
















Ovarian carcinoma (OC) is the most lethal gynaecological malignancy, accounting for over 180,000 83 
deaths per year worldwide [1]. OC is now recognised to comprise five core histological subtypes: 84 
high grade serous (HGS), endometrioid, clear cell, low grade serous (LGS) and mucinous OC – each 85 
displaying distinct molecular landscapes and clinical behaviour [2]. Within HGS cases, homologous 86 
recombination deficiency by virtue of BRCA1 or BRCA2 mutation has been associated with favorable 87 
outcome, greater sensitivity to platinum-based chemotherapy and marked benefit from poly (ADP-88 
ribose) polymerase (PARP) inhibitors [3-6]. Conversely, CCNE1 copy number gain has been 89 
associated with chemoresistance and poorer survival in this group [3, 7].  90 
While most OC cases – particularly HGS OCs - are typically sensitive to chemotherapy in the first-line 91 
setting, the majority of patients will experience disease relapse which acquires resistance to 92 
chemotherapy [8, 9]. The most common sites of recurrence are the pelvis and peritoneum [10]. 93 
Involvement of lymph nodes (LNs) at relapse is common; however, recurrence confined solely to LNs 94 
is a rare event, accounting for ≤5% of relapsed OCs [11, 12]. These isolated LN relapse (ILNR) cases 95 
have been described as a unique clinical disease entity and are thought to experience a relatively 96 
indolent disease course, with a reported median post-relapse survival (PRS) and overall survival (OS) 97 
of around 2.5-4 and >5 years, respectively [11-18].  98 
A number of previous studies have reported on the clinical outcome of apparent ILNR OC 99 
(summarised in Table 1) [11-18]. Many of these studies have reported only a small number of cases 100 
[11, 13, 17, 18], with a minority reporting larger numbers identified from multiple centres [14, 16]. 101 
To our knowledge, none of these studies have compared outcome directly to a matched extra-nodal 102 
relapse (ENR) cohort. Furthermore, they have not performed contemporary histological subtyping or 103 
molecular characterization in order to identify potential subgroups of disease with a propensity to 104 















Here, we report clinical and molecular characterization of a matched ILNR and ENR cohort with 106 
contemporary pathology review to compare the clinical outcome and molecular landscape of ILNR 107 
and ENR OC.  108 
 109 
METHODS  110 
ILNR patient identification  111 
ILNR OC cases were identified from the Edinburgh Ovarian Cancer Database (Supplementary Figure 112 
S1), wherein the clinical variables, treatment details and follow-up data of OC patients treated 113 
within the Edinburgh Cancer Centre are collected prospectively as part of routine care. Potential 114 
ILNR cases were identified using the search terms “lymph node” or “groin node” as the dominant 115 
site of relapse, yielding 161 results. Non-epithelial tumors (n=1), tumors of borderline malignancy 116 
(n=1), and primary LN serous carcinomas (n=2) were excluded.  Patients with concurrent extra-nodal 117 
disease (n=50), lack of cross-sectional imaging to confirm sole ILNR (n=13) or coexistence of other 118 
malignancies leading to uncertain origin of LN disease (n=2) were excluded. Patients with residual 119 
disease (RD) after completion of first-line treatment (n=19) or insufficient clinical data for eligibility 120 
assessment (n=24) were also excluded, leaving 49 ILNR cases.  121 
 122 
Matching of ILNR to ENR 123 
ILNR cases were electronically matched to ENR cases with complete response to first-line therapy 124 
using the Edinburgh Ovarian Cancer Database. Matching criteria were: (i) diagnostic histological 125 
subtype and grade, (ii) stage at diagnosis, (iii) extent of RD following debulking surgery and (iv) 126 
closest age at diagnosis following matching of (i)-(iii). Criteria were relaxed to facilitate matching of 127 
















Ethical approval and tissue collection  130 
Clinical research access and ethical approval for correlation of molecular data to clinicopathological 131 
features and clinical outcome in OC was obtained via NHS Lothian Research and Development 132 
(reference ID 2007/W/ON/29). Ethical approval for the use of human tumor material in translational 133 
research was obtained from South East Scotland Human Annotated Bioresource (Lothian NRS 134 
Bioresource Ethics Reference 15/ES/0094-SR831). Tumor material was available for 75.5% (74 of 98) 135 
of cases (77.6%, 38 of 49 ILNR and 73.5%, 36 of 49 ENR).  136 
 137 
Histological subtyping of ovarian carcinomas 138 
Contemporary pathology review of ILNR and matched ENR cases was performed by an expert 139 
gynaecologic pathologist (CSH). Where appropriate (n=9), immunohistochemistry (IHC) for WT1 and 140 
P53 was performed to aid histological subtyping [19]. WT1 IHC was performed using 1:1000 dilutions 141 
of antibody M3561 clone 6F-H2 (Dako, Agilent Technologies). p53 staining was performed using 1:50 142 
dilutions of antibody M7001 clone DO-7 (Dako, Agilent Technologies). Both stains were performed 143 
using the Leica Bond III Autostainer (Leica Biosystems).  144 
 145 
Nucleic acid isolation  146 
Up to ten 10µm FFPE sections, macrodissected using marked H&E-stained slides as a guide to enrich 147 
for tumor purity (supplementary table S2), were used for DNA extraction. DNA was extracted using 148 
the QIAamp DNA FFPE Tissue Kit and Deparaffinization Solution (Qiagen).  149 
 150 















High throughput sequencing was performed using an 83-gene custom Integrated DNA Technologies 152 
(IDT) gene capture panel with unique molecular indices (UMIs) as described in Appendix A. Gene 153 
targets, centred around the homologous recombination DNA repair pathway, are detailed in 154 
Supplementary Table S3. The median per-sample mean target coverage achieved was 386X.  155 
 156 
Assessment of CCNE1 copy number  157 
Copy number variants in CCNE1 were characterised by TaqMan Genotyping qPCR Copy Number 158 
Assays (Applied Biosystems, Thermo Fisher Scientific) as detailed in Appendix B.  159 
 160 
Assessment of tumor infiltrating lymphocyte density 161 
Tumor infiltrating lymphocytes (TILs) were assessed using 4µm FFPE sections of diagnostic tumor 162 
material from first-line cytoreductive surgery. IHC for CD3 and CD8 was performed using Bond 163 
ready-to-use CD8-4B11 and CD3-LN10 antibodies (Leica Biosystems) on the Leica Bond III 164 
Autostainer. Human tonsil was used as a positive control for both markers. Stained slides were 165 
digitized and marker-positive cells were quantified using QuPath [20] in eight randomly selected 166 
tumor-containing 500µm by 500µm fields per sample. Tumor area was marked as a region of 167 
interest (supplementary figure S2) and marker-positive cells were quantified using the positive cell 168 
detection protocol as a percentage of the total cell number demonstrating marker positivity. 169 
TIL scoring validation was performed by manual counting of marker-positive cells by two human 170 
observers (RLH and AHP), in a randomly selected validation cohort representing 15% of samples for 171 
each marker. The correlation of marker-positive cell counts (observer 1 vs observer 2 vs QuPath) 172 

















Statistical analyses  176 
Statistical analyses were performed using R version 3.5.1. Disease-free interval (DFI) was calculated 177 
as time from end of first-line chemotherapy to disease recurrence. Comparisons of OS and PRS were 178 
conducted using Cox proportional hazards regression models within the Survival R package [21] and 179 
presented as hazard ratios (HRs) alongside their 95% confidence intervals (CIs). Frequency 180 
comparisons were made using the Chi-squared test and Fisher’s exact test as appropriate. 181 
Comparisons of TIL density were made using the Mann Whitney-U test. Analyses were adjusted for 182 
multiplicity of testing using the Bonferroni correction, where specified.  183 
 184 
RESULTS   185 
Cohort Characteristics 186 
Demographics of the ILNR and ENR cohorts are summarised in Table 2. There was no significant 187 
difference in age at diagnosis, RD following primary surgical debulking, histology or grade of disease 188 
at diagnosis, or disease stage at diagnosis between the ILNR and ENR groups. These data indicate 189 
good fidelity of the ILNR-ENR matching process. Patterns of ILNR are described in Table 3. 190 
 191 
Clinical outcome in ILNR versus ENR 192 
ILNR patients displayed prolonged OS and PRS compared to the ENR cohort (HR=0.55 [0.34-0.87], 193 
P=0.011 and HR=0.50 [0.31-0.80], P=0.004) (Figure 1A and Figure 1B). The median OS and PRS in the 194 
ILNR cohort was 72.9 (95% CI 62.2-96.5) and 32.0 (95% CI 23.3-53.3) months, compared to 41.1 (95% 195 
CI 30.0-58.8) and 14.9 (95% CI 12.9-23.7) months in the ENR cohort. The length of the disease-free 196 
interval (DFI) prior to ILNR or ENR was not significantly different between the two cohorts (HR=0.86 197 















Multivariable analysis for OS accounting for extent of RD following primary debulking, FIGO stage 199 
and age at diagnosis identified significantly prolonged OS in the ILNR cohort (HR
multi
=0.51 [0.31-0.84], 200 
P=0.008) (Supplementary Table S4). Multivariable analysis of PRS, accounting for DFI and age 201 
identified prolonged PRS in ILNR cases (HR
multi
=0.52 [0.33-0.84], P=0.007) (Supplementary Table S5). 202 
Significantly prolonged OS (HR
multi
 for OS=0.53 [0.29-0.99], P=0.046) and PRS (HR
multi
 for PRS=0.54 203 
[0.31-0.96], P=0.037) was demonstrated for ILNR OC when considering HGS cases specifically (34 204 
ILNR HGS OCs, 31 ENR HGS OCs). 205 
 206 
Longer DFI is associated with prolonged PRS in ILNR OC 207 
The importance of DFI on clinical outcome in ILNR OC remains controversial, with some authors 208 
reporting no association between DFI length and PRS or OS in this setting [11, 16, 18] and others 209 
reporting significant associations [12, 14, 15]. Within the ILNR cohort, DFI ≥12 months was 210 
associated with markedly prolonged PRS when accounting for patient age (HR
multi
=0.38 [0.19-0.78], 211 
P=0.008), with median PRS of 47.3 versus 20.1 months in those with DFI ≥12 months and DFI <12 212 
months, respectively (Figure 1C).  213 
 214 
Impact of ILNR pattern on outcome   215 
There was no clear differential PRS between multi-region ILNR and single-region ILNR (2 regions 216 
versus single site HR=1.06 [0.49-2.30], P=0.890; ≥3 sites versus single site HR=0.94 [0.36-1.43], 217 
P=0.898).  218 
Six ILNR cases (12.2%) involved supraclavicular LN sites. While these cases demonstrated an 219 
apparent trend for inferior PRS (HR=2.52 [0.95-6.69], P=0.064) (Supplementary Figure S3), there was 220 
no significant difference after accounting for DFI and age (HR
multi
=1.63 [0.58-4.60], P=0.359). Other 221 
















Molecular landscape of ILNR HGS OC   224 
64 HGS OC cases (33 ILNR, 31 ENR) were successfully characterised for HR gene mutations and 225 
CCNE1 copy number. Frequencies of genomic abnormalities are outlined in Figure 2A and 226 
Supplementary Table S3. Within HGS OC cases, there was no significant difference in the rate of 227 
CCNE1 copy number gain (18.2%, 6/33 versus 22.6%, 7/31, P=0.900) or BRCA1/2 mutation (24.4%, 228 
8/33 vs 19.4%, 6/31, P=0.865) between the ILNR and ENR cohorts (Figure 2A). 229 
The CD3+ and CD8+ TIL burden was greater in diagnostic tumor specimens from HGS OC patients 230 
who went on to experience ILNR when compared to their ENR counterparts (median CD3+ cell 231 
density 1.94% vs 1.13%, P=0.001 and median CD8+ cell density 0.90% vs 0.45%, P=0.009; Bonferroni-232 
adjusted P=0.003 and P=0.019) (Figure 2B).  233 
 234 
COMMENT 235 
Principle findings 236 
The principle findings of this study are: (i) ILNR represents a distinct pattern of OC relapse with 237 
prolonged survival versus ENR cases; (ii) longer DFI prior to ILNR is associated with prolonged PRS in 238 
ILNR; (iii) ILNR OC do not demonstrate significantly differential composition of known genomic 239 
subtypes associated with prognosis, namely BRCA1/2 mutation or gain of CCNE1; (iv) cases that go 240 
on to experience ILNR demonstrate greater TIL burden at diagnosis compared to ENR cases.  241 
Study strengths and limitations  242 
A key strength of this study is the direct comparison of ILNR OC to matched ENR cases: a number of 243 
studies have reported ILNR as a distinct pattern of OC relapse with a relatively indolent disease 244 















Moreover, these studies did not perform pathology review of identified cases, precluding the ability 246 
to characterise ILNR outcome in the context of contemporary OC histotypes, which are now known 247 
to display markedly differential clinical outcome [22]. Critically, we characterise ILNR OC following 248 
contemporary histological subtyping to facilitate investigation of ILNR in a histotype-specific manner.  249 
The majority of previous studies investigating ILNR have identified fewer than twenty OC cases of 250 
serous histology that go on to experience this rare relapse pattern; moreover, previous reports have 251 
not performed molecular characterisation of OC cases that demonstrate ILNR [11-18]. We identified 252 
49 ILNR OC patients treated within the Edinburgh Cancer Centre, including 34 cases reviewed as HGS 253 
OC. This study represents the largest ILNR OC series from a single centre and the only report 254 
investigating the molecular landscape of ILNR OC to date.  255 
While this study does represent one of the largest reported ILNR OC cohorts, case numbers were still 256 
restricted due to the rarity of ILNR OC. In particular, power to detect differential outcome between 257 
distinct patterns of ILNR was limited, and we could not perform meaningful analysis comparing rates 258 
of rare genomic events present in both ILNR and ENR cohort, including mutational events in RB1, 259 
NF1 and PTEN, as well as gene-specific analysis of BRCA1 and BRCA2. Other limitations of this study 260 
include heterogeneous treatment of OC patients across the time period in which these cases were 261 
diagnosed, though diagnosis periods were comparable between the ILNR and ENR cohorts (Table 2).  262 
Clinical outcome in ILNR OC  263 
The median PRS and OS of ILNR cases was approximately 2.7 and 6 years, consistent with previous 264 
reports of ILNR OC [11-18]. ILNR cases displayed significantly prolonged OS and PRS compared to 265 
their ENR counterparts upon multivariable analysis (HR
multi
=0.51 and 0.52 for OS and PRS). Critically, 266 
this difference was maintained in a histotype-specific analysis of HGS cases, which account for the 267 
majority of OCs. To our knowledge, this is the first report directly demonstrating a significant 268 















Only half of the reports investigating the impact of DFI length on ILNR outcome to date have 270 
identified associations with OS or PRS [12, 14, 15]. Here, we demonstrate that DFI ≥12 months is 271 
associated with a substantial PRS benefit (median PRS approximately 3.9 versus 1.7 years), largely 272 
reflective of established associations in unselected OC cases [23]. While this contradicts reports from 273 
some investigators [11, 16, 18], two of these studies reported specifically in the context of ILNR 274 
undergoing secondary debulking [16, 18] and the other compared cases using a cut-off DFI of 24 275 
months, rather than 12 months as described here [11], potentially explaining this discrepancy. 276 
Notably, the intervals considered in our study are akin to those used clinically to define platinum 277 
sensitivity in unselected relapsed OC [23].  278 
We show no significant difference in clinical outcome between patients with ILNR at multiple sites 279 
versus those with single site ILNR, or between distinct patterns of ILNR. While univariable analysis 280 
suggested that supraclavicular LN involvement may confer inferior PRS, this trend was not apparent 281 
when accounting for DFI and patient age, suggesting that this is not a genuine phenomenon of 282 
supraclavicular ILNR. Notably, the number of patients with supraclavicular LN involvement was low 283 
(n=6). Together, these data support the consideration of ILNR OC as a single disease entity, 284 
regardless of the number and location of involved sites. 285 
The genomic landscape of ILNR OC 286 
Until now, the molecular landscape of ILNR has been completely uncharacterised. It has therefore 287 
been unclear as to whether OC cases that go on to experience ILNR demonstrate enrichment of 288 
tumors belonging to known favorable genomic subgroups. Within unselected cohorts of HGS OC, 289 
inactivation of BRCA1 or BRCA2 has been associated with favorable outcome [3, 4], while copy 290 
number gain of CCNE1 has been associated with poor survival and chemoresistance [3, 7]. Genomic 291 
characterization of this cohort did not identify significant depletion or enrichment of these 292 
molecular events in ILNR HGS OC cases versus their ENR counterparts. These data suggest that the 293 















with favourable prognosis or absence of CCNE1-gained cases which have poorer prognosis, and 295 
suggest that these genomic subgroups do not display markedly differential propensity for ILNR.  296 
Greater TIL burden at diagnosis in patients who subsequently experience ILNR 297 
Intriguingly, assessment of the CD3+ and CD8+ cell burden in ILNR and ENR tumor material – 298 
reflective of whole T-cell and cytotoxic T cell populations – uncovered significantly greater TIL 299 
burden in diagnostic tissue from patients who subsequently experienced ILNR (2-fold enrichment for 300 
CD8+ cells,  approximately 1.7-fold enrichment for CD3+ cells). These data suggest that active 301 
engagement of the immune system at diagnosis impacts upon the nature of disease at relapse, and 302 
that immune-mediated control of cancer cells may contribute to the indolent disease course of ILNR 303 
OC. Indeed, these data may well be of interest in relation to the use of immune-directed therapies in 304 
cancer treatment [24, 25]. However, while many ILNR cases displayed high TIL burden, some cases 305 
demonstrated relatively low levels of TILs, alluding to mechanisms beyond effective T cell 306 
engagement at diagnosis underpinning some ILNR cases.  307 
Conclusion 308 
Collectively, the data presented here – supported by previous descriptions of apparent ILNR in the 309 
literature – demonstrate that ILNR represents a distinct pattern of OC with favourable clinical 310 
outcome when compared to ENR. Cases that go on to experience ILNR harbour greater TIL burden at 311 
diagnosis, but do not show marked enrichment or depletion of known genomic subgroups 312 
associated with differential outcome. 313 
 314 
 315 
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Figure legends 405 
Figure 1. Clinical outcome of ILNR OC. (A) OS in ILNR vs ENR OC; (B) PRS in ILNR vs ENR OC; (C) PRS in 406 
ILNR OC by DFI length. 407 
Figure 2. Molecular landscape of ILNR and ENR OC. (A) Genomic events in ILNR and ENR cases; (B) TIL 408 
burden of ILNR and ENR HGS OCs.  409 
 410 
Supplementary figure legends 411 
Figure S1. ILNR cohort identification from the Edinburgh Ovarian Cancer Database. 412 
Figure S2. Automated marker-positive cell quantification by QuPath 413 
Figure S3. PRS of ILNR OC with and without supraclavicular LN involvement 414 
 415 
Supplementary table legends 416 
Table S1. Tolerances for electronic matching of ENR to ILNR 417 
Table S2. Cellularity of specimens used for DNA extraction 418 
Table S3. Frequency of patients with detrimental mutations in genes sequenced on IDT gene capture 419 
NGS panel 420 
Table S4. Multivariable analysis for OS in ILNR vs ENR in OC 421 
Table S5. Multivariable analysis of time to ILNR as a predictor of PRS in ILNR OC 422 














Table 1. Previous reports of ILNR OC. 
  Ferrero (16) Tu (15) Gadducci (14) Fotiou (18) Legge (12) Santillan (17) Blanchard (11) Uzan (13) Summary  
ILNR cases N 
73 38 69 21 32 25 27 12 




Years median 54 24 (63%) >50; 
14 (37%) ≤ 50 






Range  29-73 34-78 36-67 45-76 41-82 41-85 42-71 
Stage at 
diagnosis 
I 14 (19%) 0 11 (16%) 3 (14%) 0 2 (8%) 4 (15%) 5 (42%) 
II 4 (6%) 15 (39%) 6 (9%) 3 (14%) 1 (3%) 5 (20%) 5 (18%) 1 (8%) 
III 51 (70%) 23 (61%) 46 (67%) 14 (67%) 29 (91%) 15 (60%) 15 (56%) 6 (50%) 




0cm / <0.5cm 57 (78%) 17 (45%) 22 (32%) 8 (38%) 14 (44%) 18 (72%) NA 7 (58%) 
≤1cm 10 (14%) 10 (26%) 11 (16%) 7 (33%) 
6 (19%) 
5 (20%) NA 
4 (33%) 
<2cm 4 (6%) 
11 (29%) 36 (52%) 
4 (19%) 0 NA 
>2cm 2 (3%) 2 (10%) 12 (38%) 2 (8%) NA 1 (8%) 
Grade at 
diagnosis 
I 4 (6%) 7 (18%) 3 (4%) 0 
9 (32%) 25 (100%) 
high grade  NA NA 
II 5 (7%) 14 (37%) 13 (19%) 8 (38%) 
III 64 (88%) 17 (45%) 54 (78%) 13 (62%) 19 (68%) 





Serous 53 (73%) 19 (50%) 52 (75%) 16 (76%) 26 (81%) 19 (76%) 17 (62%)
a 
8 (67%) Predominantly 
serous / HGS 
cases, as with 
unselected OC 
cohorts 
Endometrioid 11 (15%) 9 (24%) 12 (17%) 
5 (24%) 
2 (6%) 2 (8%) 3 (11%) 3 (25%) 
Clear Cell 0 0 1 (1%) 0 0 0 0 
Mucinous 1 (1%) 1 (3%) 0 1 (3%) 0 3 (11%) 0 
Other  8 (11%) 9 (24%) 4 (6%) 3 (9%) 4 (16%) 4 (15%) 1 (8%) 




Median months 18 18 44 (62%)  
>12 months 
21 17.5 16 26 months from diagnosis  21 Median 1.5-2 
years DFI Range  6-192 9-96 8-156 1-134 6-40 1-159 6-72 
ILNR site(s) Para-aortic only 37 (51%) 10 (26%) 23 (33%) 8 (38%) 14 (44%) 15 (60%) 
9(33%) retro. alone, 6(22%) 
retro. + other. Supraclavicular, 
mediastinal, iliac and inguinal 
involvement in 7(26%), 4(15%), 






Pelvic only 21 (29%) 15 (39%) 12 (17%) 4 (19%) 1 (3%) 3 (12%) 4 (33%) 
Para-aortic & pevlic 9 (12%) 7 (18%) 6 (9%) 4 (19%) 9 (28%) 1 (4%) 1 (8%) 
Inguinal only 3 (4%) 2 (5%) 12 (17%) 4 (19%) 2 (6%) 5 (20%) 1 (8%) 
Other 
combinations 
3 (4%) 4 (11%) 16 (23%) 1 (5%) 6 (19%) 1 (4%) 1 (8%) 
ILNR pattern Single region 61 (84%) 27 (71%) 47 (77%) 17 (81%) 20 (63%) 24 (96%) 17 (63%) 10 (83%) Most commonly 
localised to a 
single region 
Multi-region 12 (16%) 11 (29%) 14 (23%) 4 (19%) 9 (28%) 1 (4%) 10 (37%) 2 (17%) 
NA - - 8 - 3 - - - 
PRS Median months 5-yr PRS 64%; 
5-yr OS ~80% 
5-yr PRS 66.5% 
32.1 47 37 37 26 5-yr PRS 
71% 
Median 2-4 years 
OS Median months 62.9 66 109 61 68 Median >5 years 
Surgery for 
ILNR 




No  0 19 (50%) 45 (65%) 0 20 (63%) 0 19 (70%) 0 
ILNR Chemo alone 















Surgery alone 3 (4%) 0 1 (1%) 0 1 (3%) 2 (8%) 2 (7%) 0 
Surgery-chemo 
combination 
70 (96%) 19 (50%) 22 (32%) 17 (81%) 11 (34%) 15 (60%) 5 (19%) 10 (83%) 
Radio alone 0 0 1 (1%) 0 0 0 2 (7%) 0 
No intervention  0 0 0 0 1 (3%) 0 7 (26%) 0 
Other  0 14 (37%) 1 (1%) 4 (19%) 0 8 (32%) 3 (11%) 2 (17%) 
Chemo, chemotherapy; DFI, disease-free interval; ENR, extra-nodal relapse; ILNR, isolated lymph node relapse; OS, overall survival; PRS, post-relapse survival; radio, 
radiotherapy; RD, residual disease; retro, retroperitoneal; 5-yr, 5-year; NA, not available. 
a
Includes 5 cases described as papillary; 
b













Table 2. Demographics of ILNR and ENR OC cohorts.  
 ILNR, n=49 ENR, n=49 ILNR vs ENR 
Factor Class N %/range N %/range P-value 
Stage at 
Diagnosis 
I 5 10.6 5 10.2 
1.000
a 
II 10 21.3 11 22.4 
III 27 57.4 28 57.1 
IV 5 10.6 5 10.2 
NA 2  0  
Histology at 
Diagnosis 
Serous 25 51.0 33 67.3 
.502
b 
Endometrioid 12 24.5 11 22.5 
Clear Cell 1 2.0 1 2.0 
Mixed histology  8 16.3 4 8.2 
Unclassified 
Adenocarcinoma  
3 6.1 0 0.0 
Grade at 
Diagnosis 
I 0 0.0 1 2.0 
1.000
c 
II 6 13.0 6 12.2 
III 40 87.0 42 75.7 




HGS 34 89.5 31 86.1 
.733
d 
Endometrioid  2 5.3 3 8.3 
LGS 2 5.3 1 2.8 
Mixed HGS 
/endometrioid 
0 0.0 1* 2.8 
No specimen 
available 




RD <2cm 34 75.6 33 70.2 
.733
e 
RD 2-5cm 7 15.6 8 17.0 
RD ≥5cm 4 8.9 6 12.8 
NA 4  2  
First-line 
chemotherapy 




25 51.0 28 57.1 








No 47 95.9 48 98.0 
Decade of 
Diagnosis 
≤1999 23 46.9 21 42.9 
.667
f
 2000-2005 19 38.8 23 46.9 
2006-2010 7 14.3 5 10.2 
Age at 
Diagnosis 
Median years  




Primary site 33 91.7 29 80.6 
.307
i Omentum  2 5.6 6 16.7 
Other  1
 
2.8 1 2.8 















11  13  
NA, not available; RD, residual disease. 
a
Chi-squared test, stage I/II vs stage III/IV; 
b
Chi-squared test, 
Serous/mixed versus other; 
c
Chi-squared test, grade I/II vs grade III; 
d
Fisher’s exact test, HGS versus 
non-HGS; 
e




Fisher’s exact test; 
h
Welch two-
sample T test; 
i
Fisher’s exact test, primary site vs omentum/other. *This tumour had two 















Table 3. Patterns of ILNR OC 
 Cases Proportion of cases (%) 
ILNR Pattern    
Single site  22 44.9 
Multi-regional     
2 17 34.7 
3 8 16.3 
4 2 4.1 
ILNR Sites   
Para-aortic only 16 32.7 
Pelvic only 4 8.2 
Inguinal only 2 4.1 
Pelvic & para-aortic 6 12.2 
Supraclavicular & other sites 6 12.2 
Pelvic, para-aortic & other(s) 6 12.2 









































APPENDIX A – high throughput sequencing of FFPE DNA   1 
Whole genome libraries were generated using 200ng input DNA as determined by Qubit Fluorimetry 2 
(Invitrogen, ThermoFisher Scientific). One sample failed library preparation. Libraries were pooled in 3 
groups of 16 (100ng generated library per sample) for gene capture and sequenced by the Wellcome 4 
Trust Clinical Research Facility (Western General Hospital, Edinburgh, UK) using an Illumina NextSeq. 5 
Following alignment and consensus read generation using UMIs (as detailed below), the median per-6 
sample mean target coverage achieved was 386X (range 102X – 970X).  7 
Sequence reads were processed using the bcbio v1.0.6 pipeline 8 
(https://github.com/chapmanb/bcbio-nextgen) and reads aligned against hg38 with bwa v0.7.17, 9 
sorted, then duplicate-marked with bamsormadup (biobambam v2.0.79) (1, 2). UMIs were added as 10 
tags by umis v0.9.0b0, and files were indexed after conversion to BAM format using samtools v1.6 11 
(3). Consensus reads were called and filtered with fgbio v0.4.0  12 
(https://github.com/fulcrumgenomics/fgbio) following read grouping by UMIs, then extracted with 13 
bamtofastq (biobambam), re-aligned, sorted and indexed. The aligned consensus reads underwent 14 
base quality score recalibration with the GATK v3.8 (4).  15 
Variant calling was performed using a multicaller approach: variants were called with GATK Mutect2, 16 
Freebayes (v1.1.0.46) (https://github.com/ekg/freebayes) and VarDict (Java v1.5.1) (5), then 17 
decomposed and normalized with vt v2015.11.10 (https://github.com/atks/vt). VarDict variants 18 
were annotated with vcfanno and bcftools v1.6 (6, 7). Freebayes variants were annotated with GATK 19 
VariantAnnotator. A majority vote system was used for curating high confidence calls with minimum 20 
10% variant allele frequency, with a 2/3 caller majority needed for inclusion in the final callset.  21 
Called variants were annotated using the Ensembl Variant Effect Predictor v90.9 against Ensembl 22 
release 90 (8). Variants documented as benign (as annotated by Ensembl VEP) were discarded, while 23 
documented pathogenic were retained. Remaining nonsense mutations, frameshifting indels and 24 















coding variants and missense variants of undocumented significance were discarded as variants of 26 
uncertain significance.  27 
TP53 mutations were classified independently with additional reference to the UMD TP53 variation 28 
database (9). Manual review of aligned sequence read for the supposed TP53 wild-type OCs (6 HGS, 29 
4 endometrioid, 3 LGS, 1 mixed serous/endometrioid) was performed owing to the known high TP53 30 
mutation rate in OC (particularly in HGS OCs). These analyses revealed further high confidence 31 
pathogenic mutations affecting splice sites in 4 HGS OC cases, two of which were present in the 32 
callset from a single caller and hence didn’t qualify for the ensemble callset. The apparent poorer 33 
sensitivity to splice site events was attributed to the proximity of these variants to read ends, 34 
compounded by the relatively reduced coverage at exon-intron boundaries owing to the capture 35 
design being targeted toward coding regions.   36 
 37 















APPENDIX B – CCNE1 copy number assays 39 
Copy number (CN) variants in CCNE1 were identified by TaqMan Genotyping qPCR Copy Number 40 
Assays using the StepOne Plus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, 41 
Waltham, MA, USA) and StepOne Software Version 2.3 (Life Technologies, Thermo Fisher Scientific, 42 
Waltham, MA, USA). VIC dye–labelled RNAseP TaqMan™ Copy Number Reference Assay was used as 43 
a reference assay, alongside FAM dye-labelled Hs07158517_cn targeting CCNE1. Target amplicons 44 
were chosen to ensure FFPE compatibility (87bp product for RNaseP, 91bp product for CCNE1).  45 
Amplification efficiency was assessed using serial dilutions of NA12878 genome in a bottle DNA (10) 46 
in triplicate. Efficiency was calculated using the gradient of the line of best fit for Ct value against the 47 
logarithm (base 10) of ng DNA input (efficiency = -1 + 10-1/slope of Ct versus log10 of input DNA) 48 
(11), yielding assay efficiencies of 103.4%, 97.0% and 103.3% for CCNE1, EMSY and RNaseP (RPPH1), 49 
respectively. These data indicate excellent amplification efficiency in all assays. 50 
CN assays for FFPE-derived DNA were performed alongside NA12878 DNA and FUOV1 cell line DNA 51 
controls, representing DNA with normal CN and CCNE1 CN gain, respectively (10, 12). CN variants 52 
were called using CopyCaller v2.0 (Life Technologies, Applied Biosystems, Thermo Fisher Scientific, 53 
Waltham, MA, USA) using NA12878 as calibrator sample (CN=2). CCNE1 CN ≥4 was considered CN 54 
gain. 55 
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Supplementary Table S1. Tolerances for electronic matching of ENR to ILNR 
Feature ILNR OC case documented 
diagnostic characteristic 
Matched ENR OC case documented 




Inadequate information to 
stage  
Stage II, n=1  
Stage IIIC, n=1  
3 




Adenocarcinoma Serous papillary, n=3 9 
Endometrioid Mixed serous/endometrioid, n=1 
Mixed histology Serous papillary, n=5 
Grade at 
Diagnosis 
NA Grade I, n=1 




<2cm NA, n=1 4 
NA 2-5cm, n=1  
>5cm, n=2 
Note: The matching criteria were relaxed for 2 fields for 2 patients and 3 fields for 1 patient*. NA, 
not available; RD, residual disease  
 
*1 x stage IIB grade III mixed histology carcinoma with RD <2cm matched to stage IIA grade III serous 
carcinoma with RD <2cm 
1 x stage IV unclassified adenocarcinoma of unknown grade and RD <2cm matched to stage IV grade 
III serous carcinoma with RD <2cm 
1 x stage IV unclassified adenocarcinoma of unknown grade and RD not available matched to stage 














Supplementary Table S2. Cellularity of specimens used for DNA extraction 
Tumour cellularity of 
macrodissected area 
Number of cases 
<20% 3 (4.1%) 
20-39% 7 (9.5%) 
40-59% 9 (12.2%) 
60-79% 26 (35.1%) 














Supplementary Table S3. Frequency of patients with detrimental mutations in genes sequenced on IDT gene 
capture NGS panel 
Gene ILNR OC with mutation ENR OC with mutation 
ABCB1 1 0 
ARID1A 1 2 
ATM 2 0 
ATR 1 0 
BRCA1 6 3 
BRCA2 3 3 
CTNNB1 1 1 
FANCC 0 1 
KRAS 1 1 
MSH2 1 1 
NF1 4 1 
PIK3CA 2 1 
PRKDC 1 0 
PTEN 1 1 
RB1 3 1 
SLX4 0 1 
TP53 32 31 
Genes with no detected mutations:  
ATRX, BAP1, BARD1, BCL2L1, BLM, BRAF, BRIP1, C11orf65, CCNE1, CDK12, CHD4, 
CHEK1, CHEK2, EGFR, EMSY, ERBB2, ERCC4, EZH2, FANCA, FANCB, FANCD2, FANCE, 
FANCF, FANCG, FANCI, FANCL, FANCM, GNAS, KIT, MAD2L2, MDM2, MLH1, MRE11, 
MSH6, MUS81, MUTYH, NBN, NDUFB2, NF2, NRAS, PALB2, PARP1, PARP2, PAXIP1, 
PDGFRA, PER3, PMS2, PPP2R1A, PPP2R2A, RAD50, RAD51, RAD51B, RAD51C, RAD54L, 
RNASEH2A, RNASEH2B, RNASEH2C, RPA1, RUNDC3B, SHFM1, SLC25A40, SLFN11, TOE1, 
TP53BP1, UBE2T, VRK2 














Supplementary Table S4. Multivariable analysis for OS in ILNR vs ENR in OC 
Factor Class  N HR
multi




ILNR 49 0.51 0.31 0.84 0.008 
ENR  49 Ref Ref Ref Ref 
Stage at 
Diagnosis 
Early (I/II) 31 0.41 0.17 1.02 0.055 
III 55 0.45 0.19 1.03 0.060 
IV 10 Ref Ref Ref Ref 




RD < 2cm 67 0.60 0.32 1.12 0.109 
RD ≥ 2cm 25 Ref Ref Ref Ref 
NA 6 - - - - 
Age at 
Diagnosis 
Years   1.03 1.00 1.05 0.050 














Supplementary Table S5. Multivariable analysis of time to ILNR as a predictor of PRS in ILNR OC 
Factor Class N HR
multi 
Low 95% CI Upper 95% CI P
 
Relapse type  ILNR 49 0.53 0.33 0.84 0.007 
ENR  49 Ref Ref Ref Ref 
DFI ≥12 months 46 0.47 0.29 0.75 0.006 
<12 months 52 Ref Ref Ref Ref 
Age  Years   1.03 1.01 1.06 0.006 














Supplementary Table S6. Univariable analyses of specific LN site involvement and association with PRS 




Yes 6 2.52 0.95 6.69 0.064 
No 43 Ref Ref Ref Ref 
Pelvic LN 
involvement  
Yes 20 0.73 0.35 1.51 0.393 
No 29 Ref Ref Ref Ref 
Inguinal LN 
involvement  
Yes 9 0.72 0.28 1.87 0.502 
No 40 Ref Ref Ref Ref 
Para-aortic LN 
involvement  
Yes 36 1.10 0.48 2.56 0.818 
No 13 Ref Ref Ref Ref 














































Supplementary Figure S3. PRS of ILNR OC with and without supraclavicular LN involvement 
